Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) rose 30.2% during mid-day trading on Thursday . The company traded as high as C$0.29 and last traded at C$0.28. Approximately 1,182,171 shares changed hands during trading, an increase of 75% from the average daily volume of 676,254 shares. The stock had previously closed at C$0.22.
Hemostemix Trading Up 27.9 %
The firm has a market capitalization of C$23.96 million, a P/E ratio of -13.75 and a beta of 0.20. The firm has a 50 day moving average price of C$0.10 and a 200-day moving average price of C$0.08.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- How to Invest in the FAANG Stocks
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- What Is WallStreetBets and What Stocks Are They Targeting?
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
